Author

N. J. Kingston

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Approach:biophysical modeling· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1

Frequent Co-Authors

N. J. Stonehouse· 4 shared J. S. Snowden· 3 shared K. Grehan· 3 shared D. J. Rowlands· 2 shared D. Rowlands· 2 shared J. M. Hogle· 2 shared A. J. Macadam· 1 shared A. Martyna· 1 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

N. J. Stonehouse

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Mechanism of enterovirus VP0 maturation cleavage based on the structure of a stabilised assembly intermediate.

N. J. Kingston, J. S. Snowden, K. Grehan, P. K. Hall, E. V. Hietanen, T. C. Passchier, S. J. Polyak, D. J. Filman, J. M. Hogle, D. Rowlands, N. J. Stonehouse

The paper determines the molecular mechanism of VP0 cleavage in enteroviruses using structural and bioinformatic analysis of a provirion intermediate.

bioRxiv · Apr 6, 2024Microbiology

Production of antigenically stable enterovirus A71 virus-like particles in Pichia pastoris as a vaccine candidate.

N. J. Kingston, J. S. Snowden, A. Martyna, M. Shegdar, K. Grehan, A. Tedcastle, E. Pegg, H. Fox, A. J. Macadam, J. Martin, J. M. Hogle, D. Rowlands, N. J. Stonehouse

This study produces antigenically stable EVA71 virus-like particles in Pichia pastoris, showing they retain native antigenic conformation and elicit neutralising antibodies comparable to inactivated virus vaccines.

bioRxiv · Jan 30, 2023 · PreprintImmunology

Development of Enterovirus anti-viral agents that target the viral 2C protein

R. Kejriwal, T. Evans, J. Calabrese, L. Swistak, L. Alexandrescu, M. Cohen, N. Rahman, N. Henriksen, R. C. Dash, K. Hadden, N. J. Stonehouse, D. J. Rowlands, N. J. Kingston, M. Hartnoll, S. Dobson, S. White

This study develops broad-spectrum anti-viral compounds targeting the conserved EV 2C protein, showing low IC50 values and suggesting a role for 2C in capsid assembly.

bioRxiv · Oct 6, 2022Pharmacology & Toxicology

VelcroVax: a bolt-on vaccine platform technology improves antibody titres against a viral glycoprotein in mice

N. J. Stonehouse, N. J. Kingston, K. Grehan, J. S. Snowden, M. Hassall, J. Alzahrani, G. C. Paesen, L. Sherry, C. R. Hayward, A. Roe, S. Stephen, D. C. Tomlinson, A. Zeltina, K. J. Doores, N. A. Ranson, , D. J. Rowlands

VelcroVax is a vaccine platform that enhances antibody titres against a viral glycoprotein in mice by combining a modified VLP with a SUMO-tagged antigen.

bioRxiv · Apr 22, 2022 · PreprintImmunology